Loading clinical trials...

Feasibility and Efficacy of the Ketogenic Diet in Alzheimer's Disease | Clinical Trials | Clareo Health

COMPLETEDNA

Feasibility and Efficacy of the Ketogenic Diet in Alzheimer's Disease

Alzheimer's Disease Ketogenic Diet Retention and Feasibility Trial

NCT03690193•University of Kansas Medical Center

Summary

The purpose of the KDRAFT study is to assess the feasibility and preliminary cognitive efficacy of a ketogenic diet therapy in patients with Alzheimer's disease.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Alzheimer's disease (CDR 0.5, 1, \& 2)
•Active study partner
•BMI \> 21
•English speaking

Exclusion Criteria

•BMI \< 21
•Consume greater than 14 drinks of alcohol per week
•Insulin Dependent Diabetes Mellitus
•Diagnosis of active cancer
•Myocardial infarction or symptoms of coronary artery disease (e.g. angina) in last year

Key Dates

Start Date

December 3, 2013

Primary Completion Date

January 6, 2017

Completion Date

January 6, 2017

Last Updated

October 1, 2018

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease

Interventions

Ketogenic Diet

BEHAVIORAL

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 1, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Feasibility and Efficacy of the Ketogenic Diet in Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease